Skip to main content
Premium Trial:

Request an Annual Quote

Assurex's GeneSight Gets Approval for Use in VA Facilities

NEW YORK (GenomeWeb) – Assurex Health today said that the US Department of Veterans Affairs has approved the firm's GeneSight Psychotropic test for use in VA facilities nationwide.

GeneSight Psychotropic measures and analyzes genomic variants that can affect a patient's response to a broad panel of medications prescribed for mental health conditions including depression, post-traumatic stress disorder, anxiety, bipolar disorder, and schizophrenia. The firm cited a study published last year in Pharmacogenetics and Genomics, which showed that patients whose medication selection was guided by GeneSight Psychotropic experienced a 70 percent greater improvement in depressive symptoms.

The VA approval also allows clinicians with the Department of Defense, the Bureau of Indian Affairs, and the Federal Bureau of Prisons to have access to the GeneSight Psychotropic test.

Mason, Ohio-based Assurex also offers the GeneSight MTHFR to help clinicians determine whether a patient may need additional folic acid supplementation; GeneSight ADHD for predicting response to ADHD medications; and GeneSight Analgesic for predicting response to opioid medications.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.